Contingent Consideration - Schedule of Reconciliation of Contingent Consideration Liability (Detail) - USD ($) $ in Thousands			12 Months Ended
	May 01, 2016	Apr. 01, 2016	Dec. 31, 2016	Dec. 31, 2015
Adjustment to fair value			$ (53)	$ (491)
QuaDPharma
Paid in cash	$ (700)
Polymed
Paid in cash		$ (2,500)
Significant Unobservable Inputs (Level 3) | QuaDPharma
Beginning balance			1,133
Adjustment to fair value			(106)
Satisfied through issuance of common stock			(343)
Paid in cash			(684)
Ending balance				1,133
Significant Unobservable Inputs (Level 3) | Polymed
Beginning balance			4,841
Adjustment to fair value			159
Satisfied through issuance of common stock			(2,500)
Paid in cash			$ (2,500)
Ending balance				$ 4,841